Introduction: Gene therapy is a promising approach to be applied in cardiac regeneration after myocardial infarction and gene correction for inherited cardiomyopathies. However, cardiomyocytes are crucial cell types that are considered hard-to-transfect. The entrapment of nucleic acids in non-viral vectors, such as lipid nanoparticles (LNPs), is an attractive approach for safe and effective delivery. Methods: Here, a mini-library of engineered LNPs was developed for pDNA delivery in cardiomyocytes. LNPs were characterized and screened for pDNA delivery in cardiomyocytes and identified a lead LNP formulation with enhanced transfection efficiency. Results: By varying lipid molar ratios, the LNP formulation was optimized to deliver pDNA in cardiomyocytes with enhanced gene expression in vitro and in vivo, with negligible toxicity. In vitro, our lead LNP was able to reach a gene expression greater than 80%. The in vivo treatment with lead LNPs induced a twofold increase in GFP expression in heart tissue compared to control. In addition, levels of circulating myeloid cells and inflammatory cytokines remained without significant changes in the heart after LNP treatment. It was also demonstrated that cardiac cell function was not affected after LNP treatment. Conclusion: Collectively, our results highlight the potential of LNPs as an efficient delivery vector for pDNA to cardiomyocytes. This study suggests that LNPs hold promise to improve gene therapy for treatment of cardiovascular disease.
Introduction: Gene therapy is a promising approach to be applied in cardiac regeneration after myocardial infarction and gene correction for inherited cardiomyopathies. However, cardiomyocytes are crucial cell types that are considered hard-to-transfect. The entrapment of nucleic acids in non-viral vectors, such as lipid nanoparticles (LNPs), is an attractive approach for safe and effective delivery. Methods: Here, a mini-library of engineered LNPs was developed for pDNA delivery in cardiomyocytes. LNPs were characterized and screened for pDNA delivery in cardiomyocytes and identified a lead LNP formulation with enhanced transfection efficiency. Results: By varying lipid molar ratios, the LNP formulation was optimized to deliver pDNA in cardiomyocytes with enhanced gene expression in vitro and in vivo, with negligible toxicity. In vitro, our lead LNP was able to reach a gene expression greater than 80%. The in vivo treatment with lead LNPs induced a twofold increase in GFP expression in heart tissue compared to control. In addition, levels of circulating myeloid cells and inflammatory cytokines remained without significant changes in the heart after LNP treatment. It was also demonstrated that cardiac cell function was not affected after LNP treatment. Conclusion: Collectively, our results highlight the potential of LNPs as an efficient delivery vector for pDNA to cardiomyocytes. This study suggests that LNPs hold promise to improve gene therapy for treatment of cardiovascular disease.
Authors: Kevin J Kauffman; J Robert Dorkin; Jung H Yang; Michael W Heartlein; Frank DeRosa; Faryal F Mir; Owen S Fenton; Daniel G Anderson Journal: Nano Lett Date: 2015-10-20 Impact factor: 11.189
Authors: Muthusamy Jayaraman; Steven M Ansell; Barbara L Mui; Ying K Tam; Jianxin Chen; Xinyao Du; David Butler; Laxman Eltepu; Shigeo Matsuda; Jayaprakash K Narayanannair; Kallanthottathil G Rajeev; Ismail M Hafez; Akin Akinc; Martin A Maier; Mark A Tracy; Pieter R Cullis; Thomas D Madden; Muthiah Manoharan; Michael J Hope Journal: Angew Chem Int Ed Engl Date: 2012-07-10 Impact factor: 15.336
Authors: Marvin Krohn-Grimberghe; Michael J Mitchell; Maximilian J Schloss; Omar F Khan; Gabriel Courties; Pedro P G Guimaraes; David Rohde; Sebastian Cremer; Piotr S Kowalski; Yuan Sun; Mingchee Tan; Jamie Webster; Karin Wang; Yoshiko Iwamoto; Stephen P Schmidt; Gregory R Wojtkiewicz; Ribhu Nayar; Vanessa Frodermann; Maarten Hulsmans; Amanda Chung; Friedrich Felix Hoyer; Filip K Swirski; Robert Langer; Daniel G Anderson; Matthias Nahrendorf Journal: Nat Biomed Eng Date: 2020-10-05 Impact factor: 25.671